Discontinue GLP-1RA before conception in type 2 diabetes
STEP 1 — Gather Information
Collect pregnancy intention, current GLP-1RA regimen and dosing, contraception method, HbA1c, weight, renal function, and anticipated timing of conception after contraception cessation.
STEP 2 — Rule In / Rule Out
Rule in: patient with type 2 diabetes mellitus currently on a GLP-1RA who is planning pregnancy or seeking preconception care; rule out: patient not planning pregnancy, already pregnant, has type 1 diabetes, or is not on a GLP-1RA.
STEP 3 — Classify or Stratify
Stratify by anticipated conception timing (<1 month, 1–3 months, >3 months) and GLP-1RA half‑life (short‑acting e.g., lixisenatide vs long‑acting e.g., semaglutide) to determine discontinuation window and need for insulin transition.
STEP 4 — Decide
Discontinue GLP-1RA at least 1 month before desired conception for short‑acting agents and 2 months for long‑acting agents; initiate insulin or other pregnancy‑safe antihyperglycemic agent; maintain effective contraception until conception is desired; optimize glycemia to HbA1c <6.5% before conception attempt.
Clinical Guardrails / Mimics / Pitfalls
Do not discontinue GLP-1RA without ensuring effective contraception to avoid hyperglycemia‑related teratogenicity; avoid abrupt cessation leading to weight gain and hyperglycemia; do not delay discontinuation until after pregnancy confirmation; do not neglect active glycemic management after GLP-1RA stop; do not overlook risks of prolonged time off GLP-1RA such as rebound weight gain.
Concrete Clinical Example
A 32‑year‑old woman with type 2 diabetes on semaglutide 1 mg weekly desires pregnancy in the next 3 months and uses condoms. Advise to stop semaglutide now, start basal‑bolus insulin titrated to fasting <95 mg/dL, continue contraception for another month to allow washout, then attempt conception after confirming HbA1c <6.5% and stable weight.
Source: Preexisting Diabetes and Pregnancy: An Endocrine Society and European Society of Endocrinology Joint Clinical Practice Guideline, Endocrine Society, 2025, https://doi.org/10.1210/clinem/dgaf288